Candia albicans lumbar spondylodiscitis contiguous to infected abdominal aortic aneurysm in an intravenous drug user

2021 ◽  
Vol 14 (4) ◽  
pp. e241493
Author(s):  
Tsuyoshi Yamada ◽  
Shigeo Shindo ◽  
Kazuyuki Otani ◽  
Osamu Nakai

While the incidence of spondylodiscitis is rising because of longer life expectancy and the increasing use of immunosuppressant drug, indwelling devices and spinal surgeries, the fungal aetiology remains rare, sometimes affecting intravenous drug users. Candida spondylodiscitis is an extremely rare complication post aortic aneurysm repair. It is potentially fatal due to the risk of aneurysm rupture and septic complications. The growing problem of systemic diseases caused by Candida species reflects the enormous increase of patients at risk. The treatment of this complicated entity is challenging and often requiring a multidisciplinary team. We reported the rare case of Candida spondylodiscitis contiguous to infected aortic aneurysm in a 74-year-old male intravenous drug user, to the extent which the vertebral body bony destruction progressed to need one-stage posterior and anterior spinal fusion surgery with curettage. Our surgical intervention combined with prolonged course of antifungal therapy could successfully eradicate the infection and resolve the neurological deficits.

2000 ◽  
Vol 38 (8) ◽  
pp. 3125-3127 ◽  
Author(s):  
Barbara Proust ◽  
Frederic Dubois ◽  
Yannick Bacq ◽  
Sophie Le Pogam ◽  
Sylvie Rogez ◽  
...  

We report the case of an occasional intravenous drug user who developed two successive hepatitis C virus (HCV) infections. The first infection led to seroconversion (anti-HCV antibodies detected) and the detection of HCV RNA in serum. After a spontaneous recovery (normalization of alanine aminotransferase levels and HCV RNA clearance), a second HCV infection was observed, with the recurrence of HCV viremia. Antibody directed against HCV serotype 1 was detected throughout the follow-up monitoring, but two different HCV strains were identified during the two infectious episodes: genotype 1a for the first and genotype 3a for the second. This observation shows that primary HCV infection does not confer protective immunity against subsequent infection with viruses of other genotypes. This may hamper the development of a vaccine. Conflicting results were obtained in genotyping and serotyping assays, suggesting that the serotyping method cannot be used to identify the HCV type in patients, such as intravenous drug users, who are exposed to successive HCV infections.


2015 ◽  
pp. bcr2015212447 ◽  
Author(s):  
Rohan Goel ◽  
Baskar Sekar ◽  
Mark N Payne

1996 ◽  
Vol 15 (7) ◽  
pp. 598-599 ◽  
Author(s):  
R. Blázquez ◽  
A. Pinedo ◽  
J. Cosín ◽  
P. Miralles ◽  
C. Lacruz ◽  
...  

2000 ◽  
Vol 342 (21) ◽  
pp. 1614-1615 ◽  
Author(s):  
Tze Shien Lo ◽  
Mary G. Mooers ◽  
Larry J. Wright

Cureus ◽  
2018 ◽  
Author(s):  
Abhishek Bhagat ◽  
Frank H Annie ◽  
Vallabh Karpe ◽  
Alfred Tager ◽  
Sarah Nease

2003 ◽  
Vol 70 (10) ◽  
pp. 906-908 ◽  
Author(s):  
J. Hurbanek ◽  
A. Jaffer ◽  
J W. Tomford ◽  
S. Gordon ◽  
S. Ghaffari

1996 ◽  
Vol 89 (9) ◽  
pp. 892-895 ◽  
Author(s):  
JOSEPH A. PRAHLOW ◽  
JAMES O. CAPPELLARI ◽  
SCOTT A. WASHBURN

Sign in / Sign up

Export Citation Format

Share Document